We are delighted to announce a new addition to our growing team, Sheila Soriano

Sheila Soriano

We are delighted to announce a new addition to our growing team, Sheila Soriano.

In 2019, she graduated in Chemistry from the University of Zaragoza, where she specialized in Analytical Sciences, oriented towards research and innovation, both from a chemical and biological point of view.

In 2018, during her Erasmus studies in Italy, she had the opportunity to delve into research, from an analytical approach, from the clinical and forensic side. She also completed a postgraduate degree in Health and Safety and a master’s degree in Big data and Business Intelligence.

She is part of the Arthex team, as Product Manager, contributing her extensive knowledge about chemistry. In addition, in her day to day, she carries out transversal tasks, mainly monitoring the control and manufacturing of our research programs. She has direct contact with our outsourced contract organization, CROs and scientific advisors.

In her professional career, she has always been linked to analysis and characterization using chromatography as the main technique, from the improvement of different products/ services.

“I have always been motivated to know and understand the way of things, and then put that knowledge into practice. For this reason, I am passionate about the world of research”.

Evidently, Sheila combines a specific technical profile with skills related to the business world, its management and promotion. Her main role here at Arthex, will be focused on product development and coordination of the CMC part of the business project. Welcome Sheila!

Different awards and grants recognize ARTHEx’s efforts to start up an innovative treatment for DM1

start up award PCUV

We are proud and overjoyed, the hard work of the ARTHEx’s team has earned recognition after our first-anniversary celebration. This month has been fascinating, bringing us several grants and awards at regional, national, and international levels.

The €250K funding from the Neotec program has been a resounding success. Indeed, this is the most prestigious grant for technology-based start-ups in Spain. Neotec is managed by CDTI, the governmental organism of the Spanish Ministry of Science dedicated to boost industrial R&D.

Moreover, Arthex has won additional funding from the HeadStart program of EIT Health (the network of best-in-class health innovators backed by the European Union). Participating in the second phase of the program will allow us to assess our research in samples from DM1 patients, thanks to a new collaboration with Dr. Gisela Nogales at IGTP (Badalona, Spain).

Last but not least, ARTHEx has been awarded during this month as one of the best start-ups at the regional level. ARTHEx has won the third award as the most innovative spin-off from the public universities of the Valencian Region (5UCV Startup program), has been a finalist of the contest for Biotech Startups organized by Bioval (Valencian cluster of biotechnology), and has been awarded by the VLC STARTUP CALL of the Science Park of the University of Valencia. This last award includes a new office at the Park that we look forward to opening.

“We are extremely grateful for the full confidence of all these organizations, and hopefully, with their support, we will advance in the development of a therapy for patients suffering from myotonic dystrophy”, says Dr. Beatriz Llamusi, ARTHEx’s CEO and co-founder.

 

Eric Marcusson joins ARTHEx’s  Scientific Advisory Board

September 2020:

ARTHEx expands its Scientific Advisory Board with the appointment of Eric G. Marcusson, who has an extensive experience of more than 20 years in preclinical drug development of RNA therapeutics. Currently, Dr. Marcusson has his own consultancy firm to provide expert advice to start-ups, pharma industry and venture capitalists.

He is also co-founder and CSO of Providence Therapeutics (www.providencetherapeutics.com), specialized in mRNA vaccines. Previously, he held the role of scientific director at leading companies in the RNA therapeutics field, such as Regulus Therapeutics and Ionis Pharmaceuticals.

Dr. Beatriz Llamusí, CEO and co-founder of ARTHEx has said “We are thrilled to count on Dr. Marcusson’s advice. His experience in the design and preclinical development of antisense oligonucleotides will help us to move faster towards the clinical stages”.

Dr Nicholas Jonhson, new Chief Medical Advisor

August 2020:

After closing a funding round of €4.25 million, ARTHEx confirms the professionalization of its team with the appointment of Nicholas Johnson, M.D., M.Sci., FAAN, as the Chief Medical Advisor of the company. Dr. Johnson is a physician specialist in DM1,  associate professor of Neurology and Human and Molecular Genetics, vice chair of research in Neurology at Virginia Commonwealth University and co-principal investigator of the Myotonic Dystrophy Clinical Research Network.

The co-founder and CEO of the company, Dr. Beatriz Llamusí welcomes Dr. Johnson and emphasizes his experience to consolidate the ARTHEx’s project. “Dr. Johnson is a KoL in DM1 with a strong experience on therapeutic trials in DM1 and many other inherited nerve and muscle disorders. Undoubtedly, he will play a crucial role in the design and execution of the clinical development of our therapy.”

“I am excited to assist ARTHEx in the development of novel, precision-based therapies for DM1. They have assembled a dedicated team focused on treating DM1, and have a therapy with a unique mechanism of action. I hope that we can bring this forward for our patients.” said Nicholas Johnson, M.D., M.Sci., FAAN.

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

Funding will help advance development of company’s Myotonic Dystrophy therapy

Valencia and Barcelona, Spain, and Paris, France, July 23, 2020 – Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1 (DM1), today announces it has closed a funding round of €4.25 million ($4.9M). This round completes an initial seed round of €2.7 million ($3.1M) brought by Invivo and CDTI-Innvierte in December 2019 and in June 2020 respectively. The total funds raised by Arthex since inception are now €6.95 million ($8M).

pdf iconWith the new funding provided by Advent France Biotechnology (AFB) and Invivo Ventures, Arthex can ensure that its therapy will be first-in-human trial ready by 2022; on completion of the ongoing optimization of the drug candidate and subsequent preclinical regulatory studies.

Arthex Team in Valencia

International Myotonic Dystrophy Consortium

Challenges in Myotonic Dystrophy

June 2019:

The ARTHEx Biotech team at the International Myotonic Dystrophy Consortium held from 10 to 14 June 2019 in Gothenburg, Sweden. “Challenges in Myotonic Dystrophy – from basic science to therapy”.

International Myotonic Dystrophy Consortium

 

Beatriz Llamusi and Arthex Biotech

J.P. MORGAN

37th Annual J. P. Morgan Healthcare Conference

January 2019:

ARTHEx S.L. participation at the 37th Annual J.P. Morgan Healthcare Conference, celebrated from January 7 to 10 2019 in San Francisco, California.

Participation at the 37th Annual J. P. Morgan

BIO International Convention

Meeting of the international biotechnology

June 2018:

ARTHEx S.L. participation at the BIO International Convention, the most important partnering meeting of the international biotechnology sector, which took place from June 4 to 7 2018 in Boston, Massachusetts.

BIO International Convention

Partnering meeting of the international biotechnology sector

 

 

FIPSE

Investors and Venture Capitals health innovation projects

March 2018:

The “Fundación para la Innvación y la Prospectiva en Salud en España” (FIPSE), presents to Investors and Venture Capitals health innovation projects of great impact and path, among which is the project of ARTHEx biotech S.L.

Fundación para la Innvación y la Prospectiva en Salud en España